Results 261 to 270 of about 142,523 (351)
Proteolytic degradation of regulator of G protein signaling 2 facilitates temporal regulation of Gq/11 signaling and vascular contraction [PDF]
Blumer, Kendall J. +4 more
core +2 more sources
Summary Multiple myeloma (MM) is a clonal malignancy of plasma cells characterized by frequent relapse and therapeutic resistance. G protein‐coupled receptor class C group 5 member D (GPRC5D) has emerged as a promising immunotherapeutic target due to its high and selective expression in MM cells and minimal presence in normal tissues.
Xueting Wang +3 more
wiley +1 more source
Glucose sensing and homeostasis by adipocyte GPCR. [PDF]
Hasan N, Chhabra KH.
europepmc +1 more source
Calcium activates SK channels in the intact human lens. [PDF]
Collison, DJ, Duncan, G, Rhodes, JD
core +1 more source
Artificial intelligence streamlines scientific discovery of drug–target interactions
Abstract Drug discovery is a complicated process through which new therapeutics are identified to prevent and treat specific diseases. Identification of drug–target interactions (DTIs) stands as a pivotal aspect within the realm of drug discovery and development. The traditional process of drug discovery, especially identification of DTIs, is marked by
Yuxin Yang, Feixiong Cheng
wiley +1 more source
Arrestins as Possible Drug Targets. [PDF]
Cinviz ZN +4 more
europepmc +1 more source
Psychedelics, entactogens and psychoplastogens for depression and related disorders
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley +1 more source
Is helix VIII of G protein‐coupled receptors (GPCRs) a lipid‐activated signalling sensor?
John Huynh +3 more
openalex +1 more source
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito +6 more
wiley +1 more source

